{
    "body": "Is Dupilumab used for treatment of atopic dermatitis?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27334730", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27690741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26428945", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25006719", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26836729", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27497276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27906698"
    ], 
    "ideal_answer": [
        "Yes, patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity."
    ], 
    "exact_answer": "yes", 
    "type": "yesno", 
    "id": "58df3e408acda3452900002d", 
    "snippets": [
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 149, 
            "text": "Dupilumab has demonstrated efficacy in patients with asthma and atopic dermatitis, which are both type 2 helper T-cell-mediated diseases.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836729", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 248, 
            "text": "Background Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 68, 
            "text": "Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1023, 
            "offsetInEndSection": 1161, 
            "text": "Dupilumab is a biologic agent targeted at TH2 cytokines, but indirectly impacts IgE and is an important biologic agent for atopic disease.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906698", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 74, 
            "text": "Dupilumab for the treatment of atopic dermatitis: A clinical trial review.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 143, 
            "offsetInEndSection": 255, 
            "text": "Dupilumab is a novel monoclonal antibody that was recently studied in adult patients with moderate-to-severe AD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2339, 
            "offsetInEndSection": 2472, 
            "text": "Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25006719", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 746, 
            "offsetInEndSection": 978, 
            "text": "The robust effects of dupilumab on skin inflammation and pruritus confirm the pathogenic role of IL-4 and IL-13 signaling in adult AD, and further support the application of Th2 cytokine antagonists in the treatment of this disease.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
            "endSection": "abstract"
        }
    ]
}